Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study

被引：0

作者：

Mototsugu Shimokawa

Kaname Nosaki

Takashi Seto

Kadoaki Ohashi

Masahiro Morise

Hidehito Horinouchi

Jun Sakakibara

Haruyasu Murakami

Seiji Yano

Miyako Satouchi

Shingo Matsumoto

Koichi Goto

Kiyotaka Yoh

机构：

[1] National Hospital Organization Kyushu Cancer Center,Cancer Biostatistics Laboratory, Clinical Research Institute

[2] Yamaguchi University Graduate School of Medicine,Department of Biostatistics

[3] National Hospital Organization Kyushu Cancer Center,Department of Thoracic Oncology

[4] National Cancer Center Hospital East,Department of Thoracic Oncology

[5] Okayama University Hospital,Department of Allergy and Respiratory Medicine

[6] Nagoya University Graduate School of Medicine,Department of Respiratory Medicine

[7] National Cancer Center Hospital,Department of Thoracic Oncology

[8] Hokkaido University Hospital,First Department of Medicine

[9] Shizuoka Cancer Center,Division of Thoracic Oncology

[10] Kanazawa University,Division of Medical Oncology, Cancer Research Institute

[11] Hyogo Cancer Center,Department of Thoracic Oncology

来源：

Trials | / 21卷

关键词：

Non-small cell lung cancer; Crizotinib; MET gene alteration; RT-PCR assay; Next-generation sequencing;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 90 条

[1] Maemondo M(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med. 362 2380-2388
[2] Inoue A(2010)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol. 11 121-128
[3] Kobayashi K(2014)First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med. 371 2167-2177
[4] Sugawara S(2015)Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer Transl Lung Cancer Res. 4 156-164
[5] Oizumi S(2014)Targeting MET amplification as a new oncogenic driver Cancers (Basel). 6 1540-1552
[6] Isobe H(2006)Somatic mutations lead to an oncogenic deletion of met in lung cancer Cancer Res. 66 283-289
[7] Mitsudomi T(2016)Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC) J Clin Oncol. 34 108-859
[8] Morita S(2015)Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors Cancer Discov. 5 850-849
[9] Yatabe Y(2015)Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping Cancer Discov. 5 842-946
[10] Negoro S(2014)Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC) J Clin Oncol. 32 8001-1639